Royal Bank Of Canada Lowers Bicycle Therapeutics (NASDAQ:BCYC) Price Target to $7.00

Bicycle Therapeutics (NASDAQ:BCYC) had its price target decreased by Royal Bank Of Canada from $11.00 to $7.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has a “sector perform” rating on the stock. Royal Bank Of Canada’s price target suggests a potential upside of 53.85% from the company’s previous close.

A number of other brokerages have also recently commented on BCYC. Morgan Stanley restated a “sell” rating and set a $13.00 price objective on shares of Bicycle Therapeutics in a research note on Tuesday. Citizens Jmp dropped their target price on Bicycle Therapeutics from $12.00 to $8.00 and set a “market outperform” rating on the stock in a report on Wednesday. Jefferies Financial Group raised Bicycle Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 17th. Needham & Company LLC decreased their price target on Bicycle Therapeutics from $24.00 to $15.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Truist Financial set a $8.00 price objective on shares of Bicycle Therapeutics in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $14.50.

Bicycle Therapeutics Trading Down 3.2%

Shares of BCYC stock opened at $4.55 on Wednesday. The company has a market cap of $315.63 million, a PE ratio of -1.44 and a beta of 1.65. The company’s fifty day simple moving average is $5.83 and its 200-day simple moving average is $6.78. Bicycle Therapeutics has a 52 week low of $4.47 and a 52 week high of $9.86.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings results on Tuesday, March 17th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.71. Bicycle Therapeutics had a negative net margin of 301.66% and a negative return on equity of 33.21%. The firm had revenue of $47.96 million during the quarter, compared to analysts’ expectations of $7.08 million. Equities research analysts expect that Bicycle Therapeutics will post -3.06 EPS for the current fiscal year.

Insider Transactions at Bicycle Therapeutics

In other Bicycle Therapeutics news, CEO Kevin Lee sold 10,989 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $6.46, for a total transaction of $70,988.94. Following the completion of the sale, the chief executive officer owned 618,996 shares in the company, valued at $3,998,714.16. This trade represents a 1.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Alethia Young sold 4,334 shares of Bicycle Therapeutics stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $6.49, for a total value of $28,127.66. Following the sale, the chief financial officer owned 87,081 shares in the company, valued at $565,155.69. This represents a 4.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 38,029 shares of company stock worth $251,966. Corporate insiders own 22.90% of the company’s stock.

Institutional Trading of Bicycle Therapeutics

Hedge funds have recently made changes to their positions in the stock. Assetmark Inc. increased its stake in shares of Bicycle Therapeutics by 74.9% in the third quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock worth $28,000 after buying an additional 1,552 shares during the last quarter. Clearstead Advisors LLC boosted its stake in Bicycle Therapeutics by 234.2% during the 4th quarter. Clearstead Advisors LLC now owns 4,655 shares of the company’s stock valued at $33,000 after acquiring an additional 3,262 shares during the last quarter. Pinnacle Wealth Management Advisory Group LLC acquired a new position in Bicycle Therapeutics during the 4th quarter worth $71,000. Ausdal Financial Partners Inc. acquired a new position in Bicycle Therapeutics during the 2nd quarter worth $70,000. Finally, Vontobel Holding Ltd. bought a new stake in shares of Bicycle Therapeutics in the 4th quarter worth about $71,000. Institutional investors and hedge funds own 86.15% of the company’s stock.

Bicycle Therapeutics News Summary

Here are the key news stories impacting Bicycle Therapeutics this week:

• Positive Sentiment: Oppenheimer cut its price target from $44 to $36 but maintained an “outperform” rating—still implying large upside from current levels. Read More.
• Positive Sentiment: Needham lowered its target from $24 to $15 but kept a “buy” rating, signaling continued analyst conviction despite the reduction. Read More.
• Positive Sentiment: Citizens JMP trimmed its target from $12 to $8 and kept a “market outperform” view, which supports a constructive medium‑term outlook. Read More.
• Neutral Sentiment: Royal Bank of Canada lowered its target from $11 to $7 and set a “sector perform” rating—more neutral guidance relative to prior coverage. Read More.
• Negative Sentiment: Multiple short‑interest notices flagged a “large increase” in short interest for March, although the published figures show zero shares (likely a data/reporting inconsistency). Still, headlines alone can prompt selling or caution among investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.